Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03057106
Recruitment Status : Active, not recruiting
First Posted : February 17, 2017
Last Update Posted : March 9, 2021
Sponsor:
Collaborators:
AstraZeneca
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
National Health and Medical Research Council, Australia
Information provided by (Responsible Party):
Canadian Cancer Trials Group

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : February 24, 2020
Estimated Study Completion Date : December 31, 2021
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 May 11, 2021
June 4, 2021
2 September 13, 2021
(Canceled on September 13, 2021)
November 23, 2021